Noninvasive Measurement of Interstitial Fluid Pressure as Marker of Tumor Aggressiveness


Get Permission

Increased interstitial fluid pressure in tumors can cause metastatic dissemination and treatment resistance. Study of interstitial fluid pressure has been challenging due to a lack of noninvasive imaging strategies. In a recent study, Hompland and colleagues from the Institute of Cancer Research at the Norwegian Radium Hospital in Oslo showed that interstitial fluid pressure can be measured by a noninvasive strategy using gadolinium diethylene-triamine penta-acetic acid (Gd-DTPA) as a contrast agent for dynamic contrast-enhanced MRI (DCE-MRI).

In mouse xenograft models of several types of human cancers, velocity of outward flow of a rim of Gd-DTPA high signal intensity in the tumor periphery was significantly correlated with interstitial fluid pressure. The primary tumors of mice with metastasis had higher DCE-MRI Gd-DTPA–measured fluid flow velocity and interstitial fluid pressure than the primary tumors of mice without metastasis.

These findings were confirmed in studies in patients with cervical cancer: DCE-MRI fluid flow velocity was significantly higher (P < .00001) in those with pelvic lymph node metastases compared with those without lymph node involvement.

The authors noted, “Together, these findings establish that Gd-DTPA-based DCE-MRI can noninvasively visualize tumor [interstitial fluid pressure], and they reveal the potential for v0 [fluid flow velocity] determined by this method to serve as a novel general biomarker of tumor aggressiveness.”

Hompland T, et al: Cancer Res 72:4899-4908, 2012.



Advertisement

Advertisement



Advertisement